Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review

Michael Thorpe; Ana Montalvão; Francesca Pierdomenico; Filipa Moita; António Almeida

doi:10.1016/j.leukres.2012.04.024

Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review

Michael Thorpe
, Ana Montalvão
, Francesca Pierdomenico
, Filipa Moita
, António Almeida^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

50 Citations (Scopus)

Abstract

Chronic myelomonocytic leukemia (CMML) is a clinically heterogeneous disease, with no standard treatment. We present the outcome of ten patients diagnosed with CMML and treated with AZA in our institutions between 2005 and 2010. All patients were transfusion dependent at the time of initiation of therapy. The overall response rate was 60%. Responses were obtained in 2/3 of the patients with proliferative CMML. The median survival from start of therapy was 20 months. AZA treatment was well-tolerated and associated with a significant response rate in all forms of the disease.

Original language	English
Pages (from-to)	1071-1073
Number of pages	3
Journal	Leukemia Research
Volume	36
Issue number	8
DOIs	https://doi.org/10.1016/j.leukres.2012.04.024
Publication status	Published - Aug 2012
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

5-Azacitidine
Chronic myelomonocytic leukemia
Hypomethylating agents
Myelodysplasia

Access to Document

10.1016/j.leukres.2012.04.024

Cite this

@article{a3db982d330245b99d71dba1cd9e5773,

title = "Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review",

abstract = "Chronic myelomonocytic leukemia (CMML) is a clinically heterogeneous disease, with no standard treatment. We present the outcome of ten patients diagnosed with CMML and treated with AZA in our institutions between 2005 and 2010. All patients were transfusion dependent at the time of initiation of therapy. The overall response rate was 60\%. Responses were obtained in 2/3 of the patients with proliferative CMML. The median survival from start of therapy was 20 months. AZA treatment was well-tolerated and associated with a significant response rate in all forms of the disease.",

keywords = "5-Azacitidine, Chronic myelomonocytic leukemia, Hypomethylating agents, Myelodysplasia",

author = "Michael Thorpe and Ana Montalv{\~a}o and Francesca Pierdomenico and Filipa Moita and Ant{\'o}nio Almeida",

year = "2012",

month = aug,

doi = "10.1016/j.leukres.2012.04.024",

language = "English",

volume = "36",

pages = "1071--1073",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "8",

}

TY - JOUR

T1 - Treatment of chronic myelomonocytic leukemia with 5-Azacitidine

T2 - a case series and literature review

AU - Thorpe, Michael

AU - Montalvão, Ana

AU - Pierdomenico, Francesca

AU - Moita, Filipa

AU - Almeida, António

PY - 2012/8

Y1 - 2012/8

N2 - Chronic myelomonocytic leukemia (CMML) is a clinically heterogeneous disease, with no standard treatment. We present the outcome of ten patients diagnosed with CMML and treated with AZA in our institutions between 2005 and 2010. All patients were transfusion dependent at the time of initiation of therapy. The overall response rate was 60%. Responses were obtained in 2/3 of the patients with proliferative CMML. The median survival from start of therapy was 20 months. AZA treatment was well-tolerated and associated with a significant response rate in all forms of the disease.

AB - Chronic myelomonocytic leukemia (CMML) is a clinically heterogeneous disease, with no standard treatment. We present the outcome of ten patients diagnosed with CMML and treated with AZA in our institutions between 2005 and 2010. All patients were transfusion dependent at the time of initiation of therapy. The overall response rate was 60%. Responses were obtained in 2/3 of the patients with proliferative CMML. The median survival from start of therapy was 20 months. AZA treatment was well-tolerated and associated with a significant response rate in all forms of the disease.

KW - 5-Azacitidine

KW - Chronic myelomonocytic leukemia

KW - Hypomethylating agents

KW - Myelodysplasia

UR - https://www.scopus.com/pages/publications/84862513949

U2 - 10.1016/j.leukres.2012.04.024

DO - 10.1016/j.leukres.2012.04.024

M3 - Article

C2 - 22607959

AN - SCOPUS:84862513949

SN - 0145-2126

VL - 36

SP - 1071

EP - 1073

JO - Leukemia Research

JF - Leukemia Research

IS - 8

ER -

Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this